Shenzhen YHLO Biotech Co., Ltd.

Shenzhen YHLO Biotech Co., Ltd. (YHLO) was founded in 2008 and is a publicly listed company on the Science and Technology Innovation Board (stock code: 688575). Based in Shenzhen, it specializes in the research, development, production, sales, and service of in vitro diagnostic (IVD) products. YHLO uses six IVD technology platforms and offers over 300 products covering areas such as autoimmunity, reproductive health, infection, liver disease, and respiratory diseases. Its products are used in hospitals, community clinics, and third-party testing centers, with coverage exceeding 70% in China's top-tier hospitals, and are exported to nearly 115 countries and regions.

Shenzhen YHLO Biotech Co., Ltd. (YHLO) was founded in 2008. It is a publicly listed company on the Science and Technology Innovation Board (stock code: 688575). Based in Shenzhen, YHLO specializes in the research, development, production, sales, and service of in vitro diagnostic (IVD) products. The company is recognized as a national high-tech enterprise with extensive independent intellectual property rights and has been named a National Intellectual Property Demonstration Enterprise and one of Shenzhen's Top 70 Innovative Enterprises. YHLO utilizes six advanced IVD technology platforms and offers over 300 products. Its products are widely implemented across hospitals, community clinics, and third-party testing centers, with a coverage rate exceeding 70% in China's top-tier hospitals. While rooted in the domestic market, YHLO exports products to nearly 115 countries and regions.

• 2026

  As of June 2026, more than 1,310 high-quality articles have been published in international and domestic journals using YHLO testing products, with a cumulative impact factor of up to 3,470 points.

• 2026

  YHLO participates in China-Hospeq 2026, ADLM 2026, WHX Bangkok 2026, and Autoimmunity 2026, and joins BSI's 125th Anniversary Gala.

• 2008

  Shenzhen YHLO Biotech Co., Ltd. is founded in Shenzhen, China, beginning its work in in vitro diagnostic (IVD) instruments and reagents.

• YHLO is listed on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange under stock code 688575.

• YHLO builds out six IVD technology platforms: chemiluminescence, biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography.

• YHLO's product portfolio grows to more than 300 products covering autoimmunity, reproductive health, infection, liver disease, and respiratory diseases.

• YHLO products reach hospitals, community clinics, and third-party testing centers, with coverage exceeding 70% of China's top-tier hospitals.

• YHLO expands internationally, exporting products to nearly 115 countries and regions.

To be a reliable and respected IVD enterprise

• iTLA-Intelligent Total Laboratory Automation

  Intelligent Total Laboratory Automation system

• Tenfly Phoenix Blot Analyzer

  Blot Analyzer

• 2026

  Source

Read more

1. 1YHLO-CLIA Solution-LIA Solutionen.szyhlo.com
2. 2About YHLO-YHLOen.szyhlo.com
3. 3TLA-Products-YHLOen.szyhlo.com
4. 4LIA-Products-YHLOen.szyhlo.com
5. 5Shenzhen YHLO Biotech Co., Ltd. (China)wikidata.org
6. 6蹭“脑机接口”热点误导性陈述，公司及高管合计被罚750万元csrc.gov.cn
7. 7蹭“脑机接口”热点误导性陈述，公司及高管合计被罚750万元sse.com.cn
8. 8蹭“脑机接口”热点误导性陈述，公司及高管合计被罚750万元ep.ycwb.com